Mirum Pharmaceuticals reported strong revenue growth in the fourth quarter of 2025, driven by significant increases in net product sales of LIVMARLI and Bile Acid Medicines. The company narrowed its net loss compared to the prior year and ended the period with a robust cash position, setting the stage for multiple clinical readouts in 2026.

Mirum Pharmaceuticals delivered a strong third quarter in 2025, with total revenue reaching $133 million, driven by robust sales of LIVMARLI and Bile Acid Medicines. The company also made significant advancements in its pipeline, completing enrollment for the VISTAS study and initiating a new Phase 2 study for Fragile X Syndrome, while maintaining financial discipline.

Mirum Pharmaceuticals reported strong second quarter 2025 financial results, with total revenue reaching $127.8 million, driven by robust global net product sales, especially from LIVMARLI. The company raised its full-year revenue guidance to $490 million to $510 million, reflecting confidence in its commercial momentum and pipeline advancements.

Mirum Pharmaceuticals had a strong start to 2025 with commercial growth and pipeline advancements. Total revenue for Q1 2025 was $111.6 million, a significant increase from the same period in the previous year. The company also raised its full-year 2025 revenue guidance.

Mirum Pharmaceuticals reported strong financial performance in Q4 2024, with total revenue reaching $99.4 million and a net loss of $23.79 million. The company also provided positive full-year 2025 guidance, expecting continued revenue growth and positive cash flow.

Mirum Pharmaceuticals reported Q3 2024 global net product sales of $90.3 million, representing an 89% increase compared to Q3 2023. The company increased its 2024 revenue guidance to $330-335 million. Volixibat was granted breakthrough therapy designation for treatment of cholestatic pruritus in PBC, and the PDUFA date for chenodiol in CTX is set for December 28, 2024.

Mirum Pharmaceuticals reported second quarter global net product sales of $77.8 million, a 139% increase compared to the second quarter of 2023. The company is on track to achieve full-year guidance of $310 to $320 million. Positive interim results were reported for volixibat in VISTAS PSC and VANTAGE PBC studies. LIVMARLI received marketing authorization in Europe for the treatment of PFIC.

Mirum Pharmaceuticals reported a strong first quarter of 2024, marked by a 137% increase in total revenue to $69.2 million. The company is on track to achieve its full-year revenue guidance of $310 to $320 million. Key achievements include FDA approval of LIVMARLI for cholestatic pruritus in PFIC patients and progress in regulatory and pipeline milestones.

Mirum Pharmaceuticals reported net product sales of $178.9 million for the full year 2023, representing 142% growth over 2022.

Mirum Pharmaceuticals reported a strong third quarter in 2023, marked by a significant increase in total revenue to $47.7 million, driven by LIVMARLI sales growth and the acquisition of CHENODAL and CHOLBAM.

Mirum Pharmaceuticals reported a total revenue of $37.5 million for Q2 2023, including $32.5 million from LIVMARLI net product sales. The company is acquiring CHENODAL and CHOLBAM to expand its leadership in pediatric hepatology. Four late-stage clinical trial data readouts are expected later this year.

Mirum Pharmaceuticals reported a strong start to 2023, with total revenue of $31.6 million, including $29.1 million in net product sales for LIVMARLI. The company is progressing with the global commercial launch of LIVMARLI, label expansions, and pipeline milestones.

Mirum Pharmaceuticals reported total revenue of $27.91 million for the fourth quarter of 2022, driven by net product sales of LIVMARLI, and ended the year with $251.7 million in cash, cash equivalents, restricted cash equivalents, and short-term investments.

Mirum Pharmaceuticals reported net product sales of $18.8 million for LIVMARLI in Q3 2022. The company is well positioned for European approval by the end of the year and raised its full year net product sales guidance estimate for LIVMARLI to $70 million.

Mirum Pharmaceuticals reported net product sales revenue of LIVMARLI for the quarter ended June 30, 2022 was $17.5 million. The company reported a net loss of $26.9 million, or $0.84 net loss per share. As of June 30, 2022, Mirum had cash, cash equivalents, restricted cash equivalents and investments of $225.0 million.

Mirum Pharmaceuticals reported a successful first quarter with total revenue of $12.9 million, including $10.9 million from LIVMARLI® product revenue. The company's net loss was $36.6 million, or $1.17 per share, and it had $239.9 million in cash, cash equivalents, and investments as of March 31, 2022.

Mirum Pharmaceuticals reported Q4 2021 financial results, highlighted by net product revenue of $3.1 million from LIVMARLI, marking a strong start to its commercial launch. The company also sold a Rare Pediatric Disease Priority Review Voucher for $110.0 million, contributing to a net income of $57.5 million for the quarter.

Mirum Pharmaceuticals reported licensing revenue of $5.0 million for the quarter ended September 30, 2021, and a net loss of $47.1 million, or $1.55 per share. The company's cash, cash equivalents, and short-term investments totaled $205.0 million as of September 30, 2021. The FDA approval and launch of LIVMARLI capped a transformational third quarter for Mirum.

Mirum Pharmaceuticals reported licensing revenue of $11.0 million for Q2 2021, stemming from a collaboration agreement. Total operating expenses were $48.4 million, resulting in a net loss of $43.9 million, or $1.45 per share. The company's cash, cash equivalents, and short-term investments amounted to $238.8 million as of June 30, 2021.

Mirum Pharmaceuticals reported a net loss of $50.5 million for the quarter ended March 31, 2021. The company is preparing for the potential launch of maralixibat for Alagille syndrome with a PDUFA date of September 29, 2021.

Mirum Pharmaceuticals reported a net loss of $37.2 million for the fourth quarter of 2020, with total operating expenses of $37.0 million. The company is preparing for the potential launch of maralixibat for Alagille syndrome in the U.S. in the second half of 2021, pending FDA approval, and has initiated Phase 2b programs for volixibat in various cholestatic conditions.

Mirum Pharmaceuticals reported a net loss of $21.5 million for the quarter ended September 30, 2020. The company's operating expenses were $21.7 million, and it had cash, cash equivalents, and investments of $133.7 million as of September 30, 2020.

Mirum Pharmaceuticals reported a net loss of $23.25 million for the second quarter ended June 30, 2020. The company's cash, cash equivalents, and investments totaled $149.3 million as of June 30, 2020. Significant progress was made toward making maralixibat available as an alternative to liver transplantation.

Mirum Pharmaceuticals reported its Q1 2020 financial results, highlighting a cash, cash equivalents, and investments balance of $166.1 million. The company is on track to begin the rolling submission of its NDA for maralixibat in Alagille Syndrome (ALGS) in the third quarter of 2020.

Mirum Pharmaceuticals reported a net loss of $18.0 million for the quarter ended December 31, 2019, with total operating expenses amounting to $18.7 million. The company's cash, cash equivalents, and investments stood at $140.0 million before gross proceeds from a follow-on public offering in January 2020.